AbbVie

Global biopharmaceutical company combining real-world oncology data and AI/ML-guided antibody design across its oncology and neuroscience pipelines.

AI Partnerships & Deployments

2024-01-09 — Strategic oncology data agreement with ConcertAI and Caris Life Sciences (ConcertAI and Caris Life Sciences). Multi-year partnership giving AbbVie access to Caris' real-world, multi-modal oncology database and ConcertAI's research-grade clinical data, combined with AI/ML-derived insights, to accelerate drug discovery, clinical development, and precision-medicine efforts and to optimize oncology clinical trials. Financial terms were not disclosed. Source: PR Newswire (ConcertAI release) (accessed 2026-07-29)
2023-12-05 — AI/ML antibody-discovery collaboration with BigHat Biosciences (BigHat Biosciences). Research collaboration using BigHat's AI/ML-guided Milliner platform, integrating machine learning with a high-speed wet lab, to discover next-generation therapeutic antibodies for oncology and neuroscience. BigHat received a $30 million upfront payment and may be eligible for up to approximately $325 million in aggregate R&D milestones, plus commercial milestones and royalties. Disclosed: $30M upfront; up to ~$325M in R&D milestones, plus commercial milestones and royalties. Source: PR Newswire (AbbVie release) (accessed 2026-07-29)